Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
- Conditions
- LeukemiaLymphoma
- Registration Number
- NCT00052572
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who have relapsed or refractory lymphoproliferative disorders.
- Detailed Description
OBJECTIVES:
Primary
* Determine the frequency and duration of complete and partial response rates for patients with relapsed or refractory indolent lymphoproliferative disorders treated with ixabepilone.
Secondary
* Determine the time to progression and overall survival of patients treated with this drug.
* Determine the toxicity of this drug in these patients.
OUTLINE: This is an open-label study.
Patients receive ixabepilone IV over 1 hour weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1-1.5 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety Efficacy
- Secondary Outcome Measures
Name Time Method Progression-free survival Mean and median duration of response Mean and median duration of progression-free and overall survival Probability of polymerase chain reaction negativity after treatment
Trial Locations
- Locations (2)
Vermont Cancer Center at University of Vermont
🇺🇸Burlington, Vermont, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States